Targeted Radionuclide Therapy in Patient-Derived Xenografts Using ¹⁷⁷Lu-EB-RGD.

ABSTRACT: Currently, most patients with non-small cell lung cancer (NSCLC) are diagnosed in advanced stages with a poor five-year survival rate. Therefore, intensive research aimed at finding novel therapeutic strategies has been ongoing; experimental models that reliably emulate NSCLC disease are greatly needed to predict responses to novel therapeutics. Therefore, we developed patient-derived xenograft (PDX) models of NSCLC, which we then used to evaluate the therapeutic efficacy of ¹⁷⁷Lu-EB-RGD, a peptide-based radiopharmaceutical with improved pharmacokinetics that targets integrin α_vβ₃ In this study, three different groups of NSCLC-PDXs were successfully established, all of which maintained the same IHC and genetic characteristics of the human primary tumor. The

SUBMITTER: Zhao L 

PROVIDER: S-EPMC7541553 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature